naxifylline
Small moleculeexperimental
Clinical trial activity
0 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Mechanism of action
- Adenosine A1 receptorANTAGONIST
ADORA1 antagonist
Discontinueddue to lack of oral formulation/poor solubility?
Chemistry & pharmacology
Loading structure…
SMILES
CCCn1c(=O)c2nc([C@H]3C[C@H]4C[C@@H]3[C@@H]3O[C@H]43)[nH]c2n(CCC)c1=O- Mol. weight
- 344.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3989819 ↗
- ChEMBLCHEMBL2107805 ↗
Also known as
- 1,3-dipropyl-8-(2-(5,6-epoxy)norbornyl)xanthine
- 1,3-enx
- 8-((2s,5,6-exo)-5,6-epoxy-2-norbonyl)-1,3-dipropylxanthine
- 8-((2s,5,6-exo)-5,6-epoxy-2-norbonyl)-1,3-dipropylxanthine
- adentri
- bg9719
- bg 9719
- bg-9719
- bg-9719
- bg-9719
- cvt 124
- cvt-124
- cvt-124
- cvt-124
- enx cpd
- naxifylline
- naxifylline
- naxifylline